|
|
Phio Pharmaceuticals shares are trading higher after the company announced that the Safety Monitoring Committee has concluded its review of PH-762 Phase 1b trial, reporting no serious adverse events or dose-limiting toxicities.
|
|
|
|
HC Wainwright & Co. Reiterates Buy on Phio Pharma, Maintains $14 Price Target
|
|
|
|
12 Health Care Stocks Moving In Tuesday's Intraday Session
|
|
|
|
Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients
|
|
|
|
The Safety Monitoring Committee Concluded Its Planned Safety Review For All Patients Treated With The INTASYL compound PH-762 In Phio Pharmaceuticals' Phase 1b Trial, No Serious Adverse Events Or Dose-limiting Toxicities Identified
|
|
|
|
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
|
|